SMPD1 and COVID-19: Although the mechanisms underlying this potential therapeutic effect of fluoxetine and fluvoxamine against COVID-19 are likely to be multiple and interrelated, several studies support that the interaction with the acid sphingomyelinase (ASM)/ceramide system, resulting in both antiviral and anti-inflammatory effects, may be a prominent one [13].